A new global guideline for the diagnosis and treatment of Candidainfections was recently published in Lancet Infectious Diseases1. This guideline sets out new standards for managing fungal infections, which affect millions of people worldwide every year.
The global guideline was developed by a team of more than 100 experts spanning 35 countries and led by Professor Dr. Oliver A. Cornely and Dr. Rosanne Sprute from University Hospital Cologne.
One year following the European Medical Association (EMA)2 approval, rezafungin â–¼3 has been included in the guideline, along with other echinocandins, as a strongly recommended first line therapy option for the treatment of candidaemia.
Echinocandins, including rezafungin, are preferred for all forms of invasive candidiasis, excluding CNS and ocular infections, due to their broad antifungal activity and favourable safety profile.
The new guideline, which took four years to develop, contains recommendations for clinicians on the prevention, diagnosis and treatment of various forms of candidiasis, including innovative diagnostic procedures and the latest therapeutic approaches to help improve patient care.
The guideline is supported by more than 70 international expert associations including ECMM (European Confederation of Medical Mycology), ISHAM (International Society for Human and Animal Mycology) and ASM (American Society for Microbiology), who endorse its recommendations as an important guide for healthcare professionals.
About Mundipharma
Mundipharma is a global healthcare company focussing on customers across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East.
Mundipharma is dedicated to bringing innovative treatments to patients in the areas of pain management, infectious disease as well as other severe and debilitating disease areas. Their guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything they do. For more information visit www.mundipharma.com.
